Cargando…

Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report

INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Hideki, Iizasa, Toshihiko, Ishikawa, Aki, Yoshino, Mitsuru, Shingyouji, Masato, Kimura, Masaki, Hirata, Tetushi, Odaka, Akiko, Matsubayasi, Keiko
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613411/
https://www.ncbi.nlm.nih.gov/pubmed/19055844
http://dx.doi.org/10.1186/1752-1947-2-372
_version_ 1782163179098341376
author Kimura, Hideki
Iizasa, Toshihiko
Ishikawa, Aki
Yoshino, Mitsuru
Shingyouji, Masato
Kimura, Masaki
Hirata, Tetushi
Odaka, Akiko
Matsubayasi, Keiko
author_facet Kimura, Hideki
Iizasa, Toshihiko
Ishikawa, Aki
Yoshino, Mitsuru
Shingyouji, Masato
Kimura, Masaki
Hirata, Tetushi
Odaka, Akiko
Matsubayasi, Keiko
author_sort Kimura, Hideki
collection PubMed
description INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was admitted to our hospital on 26 January 2007 with dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis. After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 × 10(5)U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon. Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites. Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally. CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites.
format Text
id pubmed-2613411
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26134112009-01-03 Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report Kimura, Hideki Iizasa, Toshihiko Ishikawa, Aki Yoshino, Mitsuru Shingyouji, Masato Kimura, Masaki Hirata, Tetushi Odaka, Akiko Matsubayasi, Keiko J Med Case Reports Case Report INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was admitted to our hospital on 26 January 2007 with dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis. After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 × 10(5)U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon. Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites. Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally. CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites. BioMed Central 2008-12-04 /pmc/articles/PMC2613411/ /pubmed/19055844 http://dx.doi.org/10.1186/1752-1947-2-372 Text en Copyright © 2008 Kimura et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kimura, Hideki
Iizasa, Toshihiko
Ishikawa, Aki
Yoshino, Mitsuru
Shingyouji, Masato
Kimura, Masaki
Hirata, Tetushi
Odaka, Akiko
Matsubayasi, Keiko
Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title_full Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title_fullStr Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title_full_unstemmed Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title_short Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
title_sort eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613411/
https://www.ncbi.nlm.nih.gov/pubmed/19055844
http://dx.doi.org/10.1186/1752-1947-2-372
work_keys_str_mv AT kimurahideki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT iizasatoshihiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT ishikawaaki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT yoshinomitsuru eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT shingyoujimasato eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT kimuramasaki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT hiratatetushi eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT odakaakiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport
AT matsubayasikeiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport